Gralla R J, Tan C T, Young C W
Cancer Treat Rep. 1979 Jan;63(1):17-20.
Chlorozotocin was given to 37 patients with advanced malignant tumors in a daily X 5 schedule at 6-week intervals. Total iv doses for each course ranged from 75 to 200 mg/m2. Myelosuppression was dose-limiting, with a platelet count depression regularly observed at doses of greater or equal to 150 mg/m2; leukopenia occurred only at the highest dose level. Nausea and vomiting were mild and uncommon. No hyperglycemia or adverse drug-related effects on renal or hepatic function were observed. No major antitumor activity occurred; however, three patients with renal cell carcinoma and one patient each with lung cancer, ovarian carcinoma, and Hodgkin's disease had minor objective decreases in tumor size. A dose range of 150--200 mg/m2 iv for each 5-day course is recommended for phase II studies.
对37例晚期恶性肿瘤患者给予氯脲霉素，采用每日1次，连续5天的给药方案，每6周为1个疗程。每个疗程的静脉注射总剂量为75至200mg/m²。骨髓抑制是剂量限制性毒性，当剂量大于或等于150mg/m²时，经常观察到血小板计数下降；白细胞减少仅在最高剂量水平出现。恶心和呕吐症状较轻且不常见。未观察到高血糖或药物对肾功能及肝功能的不良影响。未出现明显的抗肿瘤活性；然而，3例肾细胞癌患者以及各1例肺癌、卵巢癌和霍奇金病患者的肿瘤大小有轻微的客观缩小。推荐在II期研究中采用每个5天疗程静脉注射150 - 200mg/m²的剂量范围。
